温氏股份拟斥不超2.05亿元增资恒鑫生物

Core Viewpoint - The company plans to invest up to 205 million yuan in Shandong Hengxin Biotechnology Co., Ltd. through its wholly-owned subsidiary, Guangdong Wens Investment Co., Ltd. This investment is primarily focused on equity investment and does not involve direct business operations, thus avoiding any competition or related transactions with its main business [1] Group 1 - The investment will be made in collaboration with affiliated and professional investment institutions, including Wensrun Agricultural Biotechnology (Yunnan) Venture Capital Fund and Binzhou Zhikong Venture Capital Fund [1] - The investment amount is capped at 205 million yuan, which is approximately 30 million USD [1] - The investment target, Hengxin Biotechnology, operates in a different sector from the company's main business, ensuring no conflict of interest arises [1]